Diagnosis of erectile dysfunction can be used to improve screening for Type 2 diabetes mellitus.
File(s)Carrillo-Larco_et_al-2018-Diabetic_Medicine.pdf (265.44 KB)
Published version
Author(s)
Carrillo-Larco, RM
Luza-Dueñas, AC
Urdániga-Hung, M
Bernabé-Ortiz, A
Type
Journal Article
Abstract
AIMS: To assess the diagnostic accuracy of four undiagnosed Type 2 diabetes mellitus risk scores accounting for erectile dysfunction status. METHODS: This was a population-based cross-sectional study. Type 2 diabetes was defined according to a oral glucose tolerance test and self-reported physician diagnosis. Erectile dysfunction was defined according to the answer to the question, 'Have you had difficulties obtaining an erection in the last 6 months?' (yes/no). The risk scores used were the FINDRISC, LA-FINDRISC, American Diabetes Association score and the Peruvian Risk Score. A Poisson regression model was fitted to assess the association between Type 2 diabetes and erectile dysfunction. The area under the receiver-operating characteristic curve was estimated overall and by erectile dysfunction status. RESULTS: A total of 799 men with a mean (sd) age of 48.6 (10.7) years were included in the study. The overall prevalence of Type 2 diabetes was 9.3%. Compared with healthy men, men with Type 2 diabetes had 2.71 (95% CI 1.57-4.66) higher chances of having erectile dysfunction. Having excluded men aware of Type 2 diabetes status (N=38), the area under the receiver-operating characteristic curve of three of the risk scores (not the American Diabetes Association score) improved among those who had erectile dysfunction in comparison with those who did not; for example, the area under the receiver-operating characteristic curve of the LA-FINDRISC score was 89.6 (95% CI 78.7-99.9) in men with erectile dysfunction and 76.5 (95% CI 68.5-84.4) overall. CONCLUSIONS: In a population-based study, erectile dysfunction was more common in men with Type 2 diabetes than in the otherwise healthy men. Screening for erectile dysfunction before screening for Type 2 diabetes seems to improve the accuracy of well-known risk scores for undiagnosed Type 2 diabetes.
Date Issued
2018-10-22
Date Acceptance
2018-07-18
Citation
Diabetic Medicine, 2018, 35 (11), pp.1538-1543
ISSN
0742-3071
Publisher
Wiley
Start Page
1538
End Page
1543
Journal / Book Title
Diabetic Medicine
Volume
35
Issue
11
Copyright Statement
© 2018 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK. This is an open access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/30028534
Subjects
Science & Technology
Life Sciences & Biomedicine
Endocrinology & Metabolism
Adult
Aged
Blood Glucose
Comorbidity
Cross-Sectional Studies
Diabetes Mellitus, Type 2
Erectile Dysfunction
Glucose Tolerance Test
Humans
Male
Mass Screening
Middle Aged
Peru
Prevalence
Quality Improvement
Risk Factors
Humans
Diabetes Mellitus, Type 2
Blood Glucose
Glucose Tolerance Test
Mass Screening
Prevalence
Risk Factors
Cross-Sectional Studies
Comorbidity
Adult
Aged
Middle Aged
Peru
Male
Erectile Dysfunction
Quality Improvement
1103 Clinical Sciences
Endocrinology & Metabolism
Publication Status
Published online
Coverage Spatial
England
Date Publish Online
2018-07-20